STOCK TITAN

Novan to Report First Quarter 2022 Financial Results on May 16, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Novan, Inc. (Nasdaq: NOVN) will report its first quarter 2022 financial results on May 16, 2022. A conference call will be hosted by President and CEO Paula Brown Stafford at 8:30 a.m. ET to discuss these results. The call can be accessed by dialing (844) 707-0661 for domestic or (703) 318-2240 for international participants, using conference ID: 4094919. Novan is focused on developing innovative therapeutic products for skin diseases, including the treatment of viral skin infections with its lead candidate, SB206.

Positive
  • Novan's acquisition of EPI Health enhances its commercial infrastructure and market presence.
  • The company has a pipeline of products utilizing its proprietary nitric oxide-based technology platform.
Negative
  • None.

DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May 16th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (844) 707-0661 (domestic) or (703) 318-2240 (international) and referencing conference ID: 4094919. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on researching, developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel 10.3%) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

We recently completed the acquisition of EPI Health. EPI Health equips us with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, we employ approximately 100 staff, including sales personnel currently covering 42 territories, and we promote products for psoriasis, rosacea, acne and dermatoses. We also have a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com


FAQ

When will Novan report its first quarter 2022 financial results?

Novan will report its first quarter 2022 financial results on May 16, 2022.

What time is Novan's conference call for financial results?

The conference call will take place at 8:30 a.m. ET on May 16, 2022.

How can I access Novan's conference call?

The conference call can be accessed by calling (844) 707-0661 domestically or (703) 318-2240 internationally, using conference ID: 4094919.

What is Novan's main focus in dermatology?

Novan is focused on researching and developing innovative therapeutic products for skin diseases.

What product is Novan developing for viral skin infections?

Novan is developing SB206 (berdazimer gel 10.3%) for the treatment of viral skin infections, particularly molluscum contagiosum.

NOVN

NASDAQ:NOVN

NOVN Rankings

NOVN Latest News

NOVN Stock Data

2.64M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Morrisville